Patents by Inventor John W. Warren

John W. Warren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6376197
    Abstract: Interstitial cystitis (IC) is a chronic bladder disease for which the exact etiology is unknown and for which there is no reliably effective treatment. However, it is known that the bladder epithelium is often abnormal in IC. We discovered that normal, adult, human bladder epithelial cells are inhibited from proliferating by an anti-proliferative factor (APF) present in IC urine specimens. Inhibited proliferation may cause epithelial abnormalities characteristic of IC such as ulcerations and multiple tears in the bladder epithelium. We further discovered that levels of heparin binding—epidermal growth factor-like growth factor (HB-EGF), a factor known be important for epithelial cell proliferation and wound healing in other tissues, are abnormally low in the urine of patients suffering from IC as compared to asymptomatic controls or patients with acute bacterial cystitis. The invention herein is directed to the use of urine levels of HB-EGF as a diagnostic marker for IC.
    Type: Grant
    Filed: May 22, 2000
    Date of Patent: April 23, 2002
    Assignee: University of Maryland, Baltimore
    Inventors: Susan K. Keay, John W. Warren, Michael K. Hise
  • Publication number: 20020034515
    Abstract: The present invention is directed to a gene encoding an adhesin polypeptide of Proteus mirabilis, the MrpH gene, its gene product, antigenic fragments of the adhesin polypeptide and antibodies directed against the MrpH gene product and fragments thereof. The present invention is also directed to a vaccine against Proteus mirabilis and treatment of Proteus mirabilis infection with anti-adhesin antibodies.
    Type: Application
    Filed: May 22, 2001
    Publication date: March 21, 2002
    Inventors: Harry L.T. Mobley, Xin Li, John W. Warren
  • Publication number: 20020016443
    Abstract: The invention relates to a novel antiproliferative factor (APF) present in urine of patients with interstitial cystitis (IC). APF is useful as a marker for disease activity and its antagonists are useful as therapeutic medicaments for IC and other conditions associated with elevated APF. APF and its agonists are useful in the treatment of diseases associated with cell proliferation, such as bladder cancer.
    Type: Application
    Filed: April 21, 2001
    Publication date: February 7, 2002
    Inventors: Susan K. Keay, John W. Warren, Michael Kleinberg, Michael K. Hise
  • Patent number: 6156522
    Abstract: Interstitial cystitis (IC) is a chronic bladder disease for which the exact etiology is unknown and for which there is no reliably effective treatment. However, it is known that the bladder epithelium is often abnormal in IC. We discovered that normal, adult, human bladder epithelial cells are inhibited from proliferating by an anti-proliferative fact (APF) present in IC urine specimens. Inhibited proliferation may cause epthelial abnormalities characteristic of IC such as ulcerations and multiple tears in the bladder epithelium. We further discovered that levels of heparin binding--epidermal growth factor-like growth fact (HB-EGF), a factor known be important for epithelial cell proliferation and wound healing in other tissues, are abnormally low in the urine of patients suffering from IC as compared to asymptomatic controls or patients with acute bacterial cystitis. The invention herein is directed to the use of urine levels of HB-EGF as a diagnostic marker for IC.
    Type: Grant
    Filed: July 2, 1998
    Date of Patent: December 5, 2000
    Assignee: University of Maryland Baltimore
    Inventors: Susan K. Keay, John W. Warren, Michael K. Hise
  • Patent number: 5962645
    Abstract: A novel antiproliferative factor (APF) present in urine of patients with interstitial cystitis (IC) is described. This urine antiproliferative factor can serve as a marker for disease activity and its antagonists as therapeutic medicaments for IC. In addition, APF and its agonists can be used for treating diseases associated with cell proliferation.
    Type: Grant
    Filed: October 3, 1997
    Date of Patent: October 5, 1999
    Assignee: University of Maryland
    Inventors: Susan Keay, John W. Warren, Michael Kleinberg, Michael K. Hise
  • Patent number: H1753
    Abstract: A bimodal propulsion and power nuclear reactor with coaxial power and propulsion cores, each with its own primary propellant/coolant. An inner core region provides electrical power while an outer annular core region surrounding the inner core region has, passageways for heating a gaseous propellant.
    Type: Grant
    Filed: April 29, 1997
    Date of Patent: October 6, 1998
    Assignee: The United States of America as represented by the United States Department of Energy
    Inventors: John W. Warren, Abraham Weitzberg